Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.54 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17626187 | 0.93 | RAB9A (0.53) | RAB9ATRPA1PORCNRXFP1L3MBTL1 | |
| SCHEMBL17626184 | 0.93 | RAB9A (0.61) | RAB9ATRPA1PORCNRXFP1L3MBTL1 | |
| SCHEMBL17626299 | 0.90 | PORCN (0.59) | RAB9ATRPA1PORCNRXFP1L3MBTL1 | |
| SCHEMBL21935377 | 0.88 | TRPA1 (0.55) | RAB9ATRPA1PORCNRXFP1L3MBTL1 | |
| SCHEMBL21935664 | 0.87 | TRPA1 (0.52) | RAB9ATRPA1PORCNRXFP1L3MBTL1 | |
| SCHEMBL17626308 | 0.87 | MAPK1 (0.59) | RAB9ATRPA1PORCNRXFP1L3MBTL1 | |
| SCHEMBL17626216 | 0.87 | TSHR (0.53) | RAB9ATRPA1PORCNRXFP1L3MBTL1 | |
| SCHEMBL21935371 | 0.86 | RAB9A (0.48) | RAB9ATRPA1RXFP1L3MBTL1POLB | |
| SCHEMBL17636785 | 0.85 | RAB9A (0.46) | RAB9ATRPA1PORCN | |
| SCHEMBL20312670 | 0.84 | RAB9A (0.55) | RAB9ATRPA1PORCNRXFP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559495-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-02-24 | — | — | US | disclosed |
| US-20230366031-A1 | KIT FOR IDENTIFYING MALIGNANCY, AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-11-16 | — | — | US | disclosed |
| US-20230366031-A1 | KIT FOR IDENTIFYING MALIGNANCY, AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-11-16 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-11649505-B2 | Kit for identifying malignancy, and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-05-16 | — | — | US | disclosed |
| US-11649505-B2 | Kit for identifying malignancy, and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-05-16 | — | — | US | disclosed |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-01-17 | — | — | US | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-20180170932-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-06-21 | — | — | US | disclosed |
| US-9926320-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-03-27 | — | — | US | disclosed |
| US-9926320-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-03-27 | — | — | US | disclosed |
| US-9926320-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-03-27 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20160090386-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-31 | — | — | US | disclosed |
| US-20160090386-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-31 | — | — | US | disclosed |
| US-20160090386-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649505-B2 | Kit for identifying malignancy, and uses thereof | KIT, WNT1, WNT3 | RAB9A 2228/4885TRPA1 4847/4885PORCN 4185/4885 |
| US-20230366031-A1 | KIT FOR IDENTIFYING MALIGNANCY, AND USES THEREOF | KIT, WNT1, WNT3 | RAB9A 2228/4885TRPA1 4847/4885PORCN 4185/4885 |
| US-20160090386-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | RAB9A 3162/4885TRPA1 1560/4885PORCN 3761/4885 |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | RAB9A 3162/4885TRPA1 1560/4885PORCN 3761/4885 |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, WNT3 | RAB9A 3313/4885TRPA1 1933/4885PORCN 3369/4885 |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | RAB9A 3313/4885TRPA1 1933/4885PORCN 3369/4885 |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | RAB9A 3313/4885TRPA1 1933/4885PORCN 3369/4885 |
| US-20180170932-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, CTNNB1 | RAB9A 3162/4885TRPA1 1560/4885PORCN 3761/4885 |
| US-12559495-B2 | Purine diones as Wnt pathway modulators | WNT1, CTNND1, WNT3A | RAB9A 1588/4885TRPA1 468/4885PORCN 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.